In-Depth Examination Of 11 Analyst Recommendations For AbbVie
Portfolio Pulse from Benzinga Insights
Analysts have varied ratings for AbbVie (NYSE:ABBV), with recent evaluations showing a bullish trend. The average 12-month price target has increased to $208.09, reflecting a 6.22% rise. AbbVie shows strong financial performance with high net margins and ROE, but faces challenges with high debt levels.
October 07, 2024 | 7:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AbbVie has received predominantly bullish analyst ratings, with an increase in the average 12-month price target to $208.09. The company's strong financial performance is highlighted by high net margins and ROE, though it faces challenges with high debt levels.
The majority of analysts have raised their ratings and price targets for AbbVie, indicating a positive outlook. The increase in the average price target suggests potential upward movement in the stock price. However, the high debt-to-equity ratio could pose a risk, but the overall sentiment remains positive.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100